Last reviewed · How we verify
nPEP
At a glance
| Generic name | nPEP |
|---|---|
| Also known as | Biktarvy, Bictegravir/emtricitabine/tenofovir alafenamide, BIC/FTC/TAF |
| Sponsor | Unity Health Toronto |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Improving HIV Prevention and Substance Use Post-Sexual Assault Services (NA)
- Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men (NA)
- Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (PHASE4)
- Come As You Are - Assessing the Efficacy of a Nurse Case Management HIV Prevention and Care Intervention Among Homeless Youth (NA)
- Connecting Resources for Urban Sexual Health (NA)
- PEEP Mask for Tracheobronchomalacia-Induced Cough (NA)
- HIV Non-Occupational Post-Exposure Prophylaxis (PHASE4)
- Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nPEP CI brief — competitive landscape report
- nPEP updates RSS · CI watch RSS
- Unity Health Toronto portfolio CI